Condition
Facial Angiofibroma
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results75% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Completed3
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03826628Phase 2CompletedPrimary
Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
NCT02654340Terminated
Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)
NCT03140449Phase 3CompletedPrimary
Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis
NCT01853423Phase 1CompletedPrimary
Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream
Showing all 4 trials